Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Thompson, Ella R ^a   Rowley, Simone M ^a   Sawyer, Sarah ^a   Eccles, Diana M ^b   Trainer, Alison H ^a,c   Mitchell, Gillian ^a,c   James, Paul A ^a,c   Campbell, Ian G ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER PATIENT; CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; EXON; FAMILY HISTORY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; ONCOGENE; OUTCOME ASSESSMENT; OVARY CANCER; RAD51D GENE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

AGED; AMINO ACID SEQUENCE; BASE SEQUENCE; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FAMILY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; OVARIAN NEOPLASMS;

EID: 84872844753     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054772     Document Type: Article

References (22)

1. Masson J-Y, Tarsounas MC, Stasiak AZ, Stasiak A, Shah R, et al. (2001) Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes & Development 15: 3296-3307.
2. Smiraldo PG, Gruver AM, Osborn JC, Pittman DL, (2005) Extensive Chromosomal Instability in Rad51d-Deficient Mouse Cells. Cancer Research 65: 2089-2096.
3. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, et al. (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43: 879-882.
4. Osher DJ, De Leeneer K, Michils G, Hamel N, Tomiak E, et al. (2012) Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. Br J Cancer 106: 1460-1463.
5. Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, et al. (2012) A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. J Med Genet.
6. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, et al. (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121: 353-357.
7. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, et al. (2012) BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology.
8. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, et al. (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20: 3278-3288.
9. Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, et al. (2011) Analysis of RAD51C Germline Mutations in High-Risk Breast and Ovarian Cancer Families and Ovarian Cancer Patients. Hum Mutat 33: 95.
10. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD, et al. (1996) Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res 56: 719-721.
11. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, et al. (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8: R12.
12. Baxter SW, Choong DY, Eccles DM, Campbell IG, (2002) Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 11: 211-214.
13. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, et al. (2008) Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10: 1253-1258.
14. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
15. Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R, (2009) Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat 30: 1237-1244.
16. Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, et al. (2009) Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 25: 2744-2750.
17. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, et al. (2005) PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21: 3176-3178.
18. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D, (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 7: 575-576.
19. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, et al. (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37: e67.
20. Wickramanyake A, Bernier G, Pennil C, Casadei S, Agnew KJ, et al. (2012) Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecol Oncol 127: 552-555.
21. The 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073.
22. Grantham R, (1974) Amino acid difference formula to help explain protein evolution. Science 185: 862-864.